Printer Friendly

NICE rejects AstraZeneca's Faslodex.

M2 EQUITYBITES-February 2, 2018-NICE rejects AstraZeneca's Faslodex

(C)2018 M2 COMMUNICATIONS http://www.m2.com

In its final guidelines, the National Institute for Health and Care Excellence (NICE) has rejected AstraZeneca's (LON: AZN) Faslodex (fulvestrant) as a treatment option for certain patients with breast cancer, Pharma Times reported on Friday.

The watchdog did not recommend the drug, as per the marketing authorisation, as a treatment for locally advanced or metastatic oestrogen-receptor positive breast cancer in postmenopausal women who have not previously had endocrine therapy.

Data from the Phase III FLACON trial demonstrated median progression-free survival (PFS) as being significantly longer with Faslodex when compared to anastrozole, with 16.6 months and 13.8 months, respectively.

NICE noted, however, the final data on the drug's impact on overall survival would not be expected until the end of next year. This made it unclear as to whether it would extend overall survival compared to the current standard of treatment with aromatase inhibitors. The body concluded, therefore, that the cost-effectiveness of the drug compared to existing treatments was "highly uncertain".

Faslodex was approved for first-line use in breast cancer patients in Europe in July 2017.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Feb 2, 2018
Words:203
Previous Article:Puma Biotechnology and CANbridge Life Sciences enter exclusive licensing agreement.
Next Article:Tera Ventures to raise second seed fund.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters